Biocryst Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2013.
“The fact that we met all of our goals for the BCX4161 Phase 1 trial and secured government funding for the peramivir NDA filing represents a significant step forward for BioCryst,” said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst.
Hey, check out all the research scientist jobs. Post your resume today!
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2013.
“The fact that we met all of our goals for the BCX4161 Phase 1 trial and secured government funding for the peramivir NDA filing represents a significant step forward for BioCryst,” said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst.
Hey, check out all the research scientist jobs. Post your resume today!